After coronary angioplasty, the arteries heal by a series of complex and dynamic mechanisms, which aim to restore vessel architecture and ensure laminar flow. With stent implantation, foreign material is introduced: an additional variable that significantly disturbs the healing process. Ideally, the stent struts should be covered by a perfectly functioning neo-endothelium, but this is not always the case. At different stages, peri-strut components induce inflammation with cell infiltration, fibrin, and clot formation. Patient and plaque factors play a role in healing, but we know from early-generation drug-eluting stents (DES) with permanent polymer (PP) that stent factors are crucial. The absence of strut coverage and increased fibrin formation were shown to be pathological correlates of delayed arterial healing in early-generation DES. Chronic inflammation, eosinophilic infiltrates suggesting a hypersensitivity reaction, strut malapposition, bifurcation stenting, or strut penetration of a necrotic core are other mechanisms of delayed arterial healing, precipitating stent thrombosis (ST).
The Achilles' 'heal' of stenting After coronary angioplasty, the arteries heal by a series of complex and dynamic mechanisms, which aim to restore vessel architecture and ensure laminar flow. With stent implantation, foreign material is introduced: an additional variable that significantly disturbs the healing process. Ideally, the stent struts should be covered by a perfectly functioning neo-endothelium, but this is not always the case. At different stages, peri-strut components induce inflammation with cell infiltration, fibrin, and clot formation. Patient and plaque factors play a role in healing, but we know from early-generation drug-eluting stents (DES) with permanent polymer (PP) that stent factors are crucial. The absence of strut coverage and increased fibrin formation were shown to be pathological correlates of delayed arterial healing in early-generation DES. Chronic inflammation, eosinophilic infiltrates suggesting a hypersensitivity reaction, strut malapposition, bifurcation stenting, or strut penetration of a necrotic core are other mechanisms of delayed arterial healing, precipitating stent thrombosis (ST). 1, 2 In particular, the lingering polymer has been held accountable for on-going inflammation and local hypersensitivity. The interventional community hoped to decrease chronic inflammation and hypersensitivity by creating more biocompatible and/or bioabsorbable materials. In the randomized controlled CENTURY II trial, the sirolimuseluting BP-DES Ultimaster TM [bioabsorbable polymer sirolimuseluting stent (BP-SES)] was shown non-inferior to newer generation PP-EES for target lesion failure at 9 months. 4 This study was robust, but long-term safety outcomes still need to be demonstrated as sirolimus has been associated with hypersensitivity and very late ST.
Seeing is believing
Optical coherence tomography (OCT) allows high-resolution assessment of vessel wall and is especially useful to assess vascular healing, strut coverage, and stent apposition after implantation ( Figure 1 ). Incomplete stent apposition at 8 months has been associated with a higher rate of myocardial infarction and ST during longterm follow-up. 5 Few studies are adequately powered to detect significant differences in low-frequency events such as late and very late ST, so assessing vascular healing as a surrogate marker of late adverse events is of utmost importance. So far, OCT analyses suggest that first-generation BP-DES present with more uncovered and malapposed struts than everolimus-eluting stents with persistent polymers. 6, 7 Kuramitsu et al. 8 present an OCT sub-study of the CENTURY II
trial. An angiography sub-study of the main trial had previously shown increased late-lumen loss of the BP-DES. Kuramitsu et al. present the OCT findings of 13 BP-SES-(Ultimaster TM ) and 14 PP-EES-(Xience TM ) treated patients, 9 months after stent implantation. All patients were enrolled at Kokura Memorial Hospital and underwent
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either intravascular ultrasound-or OCT-guided stent implantation. Baseline patient and lesion characteristics were simple. At 9 months OCT imaging, both devices showed similar neointimal thickness (BP-DES: 110 + 10 mm vs. PP-DES: 93 + 9 mm, P ¼ 0.22) as well as similar low rates of uncovered (BP-DES: 1.02% vs. PP-DES: 2.26%, P ¼ 0.53) or malapposed struts (BP-DES: 0.10% vs. PP-DES: 0.11%, P ¼ 0.94). The authors conclude that vascular healing at 9 months after implantation of BP-SES is excellent.
The authors should be congratulated for providing the first OCT data on vascular healing beyond 6 months after Ultimaster TM implantation. The low proportion of uncovered or malapposed struts, as well as a mean neointimal thickness comparable to other best-in-class DES, is reassuring.
However, a number of limitations need to be addressed. The absence of acute coronary syndromes and, in particular, ST-elevation myocardial infarction (STEMI) at the index procedure is one of the main limitations, which precludes any conclusion regarding vascular healing in this patient subgroup. STEMI is associated with an increased risk for the occurrence of ST and it is especially in these patients that vascular healing would be of interest. Secondly, due to the small patient sample, random variation may have played an important role as it probably does in most of the published OCT studies.
Furthermore, recent observations derived from OCT analysis of devices using bioabsorbable technology have shown a decrease in peri-strut intensity over time and in patients presenting with late or very late ST. 9 Whether this morphological finding represents an innocuous phase of bioresorption or a thrombogenic process, such as vascular oedema or inflammation, is not known. The association with device thrombosis is still a hypothesis. However, we believe that assessment of peri-strut intensity should be an integral part of OCT analysis, particularly for devices relying on bioabsorbable technology. Based on the current findings, one may conclude that low-to intermediate-risk patients have a favourable vascular response 9 months after Ultimaster TM stent implantation.
Doubting Thomas
In a way, OCT technology has opened our eyes and shown us how stent implantation influences/disturbs coronary vessels. The quest for the perfect stent is harsh and every effort should be made to minimize the interference with the organisms' natural healing process. It may well be that the miracles to come will not lie in what we see, but in what we won't anymore.
